Tower Research Capital LLC TRC Purchases 1,640 Shares of Sotera Health (NASDAQ:SHC)

Tower Research Capital LLC TRC grew its position in shares of Sotera Health (NASDAQ:SHC) by 37.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,975 shares of the company’s stock after buying an additional 1,640 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Sotera Health were worth $82,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Voss Capital LP lifted its stake in Sotera Health by 42.9% in the fourth quarter. Voss Capital LP now owns 500,000 shares of the company’s stock worth $6,840,000 after acquiring an additional 150,000 shares during the period. MetLife Investment Management LLC lifted its position in shares of Sotera Health by 9.1% in the 4th quarter. MetLife Investment Management LLC now owns 86,177 shares of the company’s stock worth $1,179,000 after purchasing an additional 7,174 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Sotera Health by 27.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,143,955 shares of the company’s stock valued at $43,004,000 after purchasing an additional 673,979 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Sotera Health by 53.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 15,300 shares of the company’s stock valued at $209,000 after purchasing an additional 5,300 shares in the last quarter. Finally, Walleye Capital LLC increased its position in shares of Sotera Health by 818.2% during the fourth quarter. Walleye Capital LLC now owns 775,000 shares of the company’s stock valued at $10,602,000 after buying an additional 690,597 shares during the period. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on SHC shares. Barclays lowered their price objective on shares of Sotera Health from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group upgraded Sotera Health from a “neutral” rating to a “buy” rating and lifted their price target for the company from $14.00 to $17.00 in a research report on Monday, May 5th. Finally, Piper Sandler decreased their price objective on Sotera Health from $15.00 to $13.00 and set a “neutral” rating for the company in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.80.

Sotera Health Price Performance

SHC stock opened at $13.13 on Friday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The firm has a 50 day moving average price of $11.45 and a 200-day moving average price of $12.93. Sotera Health has a 52-week low of $9.53 and a 52-week high of $17.08. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of 52.52 and a beta of 1.88.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The company had revenue of $254.52 million during the quarter, compared to analyst estimates of $245.56 million. During the same quarter last year, the company earned $0.13 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Equities research analysts forecast that Sotera Health will post 0.61 EPS for the current fiscal year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.